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Background
Great attention has been given towards prevention and treatment of cancers with 
respect to the impact of disease sequelae on long term well-being of individuals (Vos 
et al. 2012). Cancers have been reported as one of the Global Burden of Diseases (World 
Health Organization 2008) and are estimated to be one of main causes of death in the 
coming decades (Mathers and Loncar 2006; Soerjomataram et al. 2012). Therefore, the 
search for novel anticancer agents has become one of prime interests in drug discovery 
and development.
1,2,3-Triazoles are nitrogen heterocycles capable of forming hydrogen bonds which 
improves their solubility and ability to interact with biomolecular targets (Vatmurge 
et al. 2008). The 1,2,3-triazoles are highly stable to metabolic degradation as compared to 
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other compounds containing three adjacent nitrogen (N) atoms (Vatmurge et al. 2008). 
The triazoles have been used for broad therapeutic applications due to their diverse bio-
logical activities (Agalave et  al. 2011) i.e., antimicrobial (Shivarama Holla et  al. 1998; 
Prasad et al. 2009; Turan-Zitouni et al. 2005), antiviral (Masuda et al. 1975), antiinflam-
matory (Almasirad et al. 2004), analgesic (Almasirad et al. 2004), anticancer (Holla et al. 
2002; Shivarama Holla et  al. 2003; Pingaew et  al. 2014a, b), antifungal (Manclús et  al. 
2008) and anticonvulsant (Amir and Shikha 2004) activities. In this regards, these priv-
ileged scaffolds have drawn considerable attention in the field of medicinal chemistry 
(Kumar and Kavitha 2013).
The computational approaches are widely known for their effectiveness in facilitat-
ing drug design and discovery (Kaul 1998). Quantitative structure–activity relationships 
(QSAR) is an in silico method for correlating structures of the compounds with their 
biological activities (Nantasenamat et al. 2009, 2010). QSAR can significantly reduce cost 
and time of drug discovery pipeline (Perkins et al. 2003) since the method provides ben-
eficial knowledge for rational drug design such as crucial properties or moieties required 
for potent activities and pharmacokinetic information (Hansch et al. 2004). The QSAR 
models have been successfully constructed for understanding structure–activity rela-
tionships (SAR) of a wide range of bioactive compounds and diverse biological activities 
(Prachayasittikul et al. 2014; Nantasenamat et al. 2014; Worachartcheewan et al. 2012, 
2013, 2014a, b, c).
Structural modification is extensively used to obtain potential lead compounds with 
improved potency and pharmacokinetic properties as well as reduced toxicities (Hughes 
et al. 2011; Anderson 2003; Prachayasittikul et al. 2014). The lack of structural diversity 
is one of current problems in the field of drug discovery which leads the growing aware-
ness on expansion of chemical space (Barker et  al. 2013; Dandapani and Marcaurelle 
2010). The modification on privileged scaffolds is one of efficacious strategies to increase 
structural diversity thereby potentially addresses current issue. In addition, structural 
modification on the triazole pharmacophore has been noted as an efficient concept in 
the search for novel triazole drugs (Chrysina et al. 2009; Pingaew et al. 2014a, b).
Recently, a set of novel disubstituted 1,2,3-triazole derivatives (1–32, Fig. 1) has been 
reported as cytotoxic agents against four cancer cell lines i.e., HuCCA-1, HepG2, A549 
and MOLT-3 by our research group (Pingaew et al. 2014a, b). Molecular docking of the 
tetrahydroisoquinoline-triazole derivatives 16–32 revealed that an aldo–keto reductase 
1C3 (AKR1C3) has been identified to be a plausible target responsible for their antican-
cer activity (Pingaew et al. 2014a). In addition, the 1,2,3-triazoles (2–7, 12–13 and 15) 
were shown to be aromatase inhibitors (Pingaew et al. 2015). The 1,2,3-triazole ring can 
be synthesized using copper catalyzed azide-alkyne cycloaddition (CuAAC), known as 
the Click reaction. The analytical data of the reported compounds is provided in sup-
plementary data. These triazoles were substituted by phenylsulfonyl (opened and closed 
chain analogs containing substituent R1) at position 1; and by R group as phenyl and 
phenyl(naphthalenyl/coumaryl)oxymethyl at position 4. General core structures of com-
pounds 1–32 are summarized as opened chain (1–15) and closed chain sulfonamides 
(16–32) as shown in Fig.  2. Triazole and sulfonyl moieties of compounds 1–32 are 
substituted at 1,4-positions (para-) of the phenyl ring. For simplification, compounds 
1–32 will be denoted as para-trizoles. In this study, the QSAR was employed as a tool 
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for understanding SAR of these 1,2,3-triazole derivatives. Four QSAR models were con-
structed using the chemical structure of the 32 tested compounds (1–32) along with 
their experimental cytotoxic activity. Furthermore, the application of constructed QSAR 
models were extended for the prediction of cytotoxic activity of an additional set of 64 
structurally modified compounds (1A–1R, 2A–2R, 7A–7R and 8A–8R, Figs.  3, 4, 5, 
6) constructed in silico. Such structural modification of the compounds was rationally 
designed based on hydrophobic, electronic and steric effects as previously described by 
Topliss (1972, 1977). Therefore, the structurally modified compounds were obtained on 
the basis of changing groups on core structure (opened or closed chain), adding func-
tional groups and altering the substitution positions of triazole and sulfonyl moieties 
on the phenyl ring (i.e., para- and meta-) to give para- and meta-triazoles, respectively 
(Fig. 7). A comprehensive analysis revealed important properties, crucial moieties and 
rigid analogs necessary for potent cytotoxic activity of the triazole compounds which 
Fig. 1 Chemical structures of tested compounds 1–32
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The data for QSAR analysis was obtained from the literature reported by our research 
group (Pingaew et  al. 2014a, b). Analytical data of the reported compounds is pro-
vided in Additional file  1. The experimental cytotoxic activities (IC50) of the tested 
Fig. 2 The substitutions on opened (1–15) and closed (16–32) chain core structures of 1,2,3-triazole
Fig. 3 Chemical structures of modified compound series 1 (1A–1R)
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compounds (1–32) are shown in Table  1. The compounds (1–32) were classified by 
their IC50 values into four classes i.e., highly active (IC50  <  1  µM), moderately active 
(1  µM  <  IC50  <  10  µM), weakly active (IC50  >  10  µM) (Pérez-Sacau et  al. 2007) and 
inactive (IC50 > 50 µg/mL) (Prachayasittikul et al. 2014). All inactive compounds were 
excluded from the QSAR analysis. Four QSAR models were separately constructed 
based on experimental testing against four cancer cell lines.
Obtaining informative descriptor values
Chemical structures of 32 triazole derivatives (1–32) were drawn, geometrically opti-
mized, and calculated to obtain a set of descriptor values containing 13 quantum 
chemical descriptors and 3,224 molecular descriptors. The feature selection using cor-
relation-based followed by stepwise multiple linear regression (MLR) methods was per-
formed to select a set of significant informative descriptors of each cell line in which 
their definitions and values are shown in Table 2 and Additional file 2, respectively.
Fig. 4 Chemical structures of modified compound series 2 (2A–2R)
Fig. 5 Chemical structures of modified compound series 7 (7A–7R)
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QSAR analysis
The multiple linear regression (MLR) is one of the most popularly used machine learning 
algorithms for understanding SAR and it has been successfully employed for predicting 
bioactivities of diverse classes of compounds (Prachayasittikul et al. 2014; Worachartch-
eewan et al. 2012, 2013, 2014b, c). Regarding cytotoxic activity against four cancer cell 
lines, the data were separated into four data sets for QSAR analysis. Four QSAR mod-
els were successfully constructed by MLR method using a set of selected informative 
descriptor values and experimental cytotoxic activities (pIC50). The QSAR models and 
Fig. 6 Chemical structures of modified compound series 8 (8A–8R)
Fig. 7 Modification on 1,2,3-triazole scaffold series 1, 2, 7 and 8
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their predictive performance parameters are summarized in Table  3. Acceptable pre-
dictive performances were obtained from all constructed QSAR models with Rcv and 
RMSEcv values ranging from 0.5958 to 0.8957 and 0.2070–0.4526, respectively. The 
Table 1 Experimental cytotoxic activity of triazoles 1–32 against four cancer cell lines
The compounds (1–32) were classified by their IC50 values into four classes i.e., highly active (IC50 < 1 µM), moderately active 
(1 µM < IC50 < 10 µM), weakly active (IC50 > 10 µM) (Pérez‑Sacau et al. 2007) and inactive (IC50 > 50 µg/mL) (Prachayasittikul 
et al. 2014). All inactive compounds were excluded from the QSAR analysis. Four QSAR models were separately constructed 
based on experimental testing against four cancer cell lines
a Highly active compound
b Moderately active compound
c Weakly active compound
d Inactive compound




HuCCA-1 HepG2 A549 MOLT-3
1 8.65 ± 1.70b 9.07 ± 1.15b 34.54 ± 0.89c Inactived
2 Inactived 57.54 ± 8.66c Inactived Inactived
3 Inactived 28.21 ± 2.89c Inactived 74.23 ± 5.08c
4 Inactived 81.75 ± 2.89c Inactived Inactived
5 87.89 ± 0.92c 100.54 ± 2.12c Inactived 32.02 ± 0.76c
6 Inactived Inactived Inactived 61.42 ± 1.01c
7 Inactived 41.62 ± 1.15c Inactived 34.24 ± 3.11c
8 Inactived 49.40 ± 4.04c Inactived 8.81 ± 0.42b
9 Inactived 57.52 ± 6.51c 79.18 ± 14.15c 9.22 ± 0.48b
10 Inactived 34.51 ± 4.36c 39.04 ± 0.37c 10.33 ± 0.08c
11 16.12 ± 0.71c 12.44 ± 1.71c 19.60 ± 2.33c 88.97 ± 3.42c
12 Inactived Inactived Inactived 10.65 ± 0.48c
13 Inactived 23.89 ± 3.00c 18.19 ± 0.35c 60.99 ± 6.66c
14 Inactived Inactived 28.03 ± 1.63c 17.43 ± 0.41c
15 Inactived Inactived Inactived 10.10 ± 0.27c
16 51.35 ± 5.66c Inactived Inactived Inactived
17 Inactived 6.50 ± 0.14b Inactived Inactived
18 Inactived 60.48 ± 14.14c Inactived Inactived
19 Inactived Inactived 66.30 ± 0.70c Inactived
20 30.16 ± 4.07c 19.12 ± 3.06c 14.90 ± 1.02c 21.86 ± 3.67c
21 0.63 ± 0.04a,e 12.36 ± 1.97c 0.57 ± 0.02a,e 18.63 ± 1.62c
22 Inactived 5.27 ± 0.71b 59.07 ± 11.31c Inactived
23 24.80 ± 2.19c Inactived 25.29 ± 10.78c 80.78 ± 10.23c
24 72.0 ± 10.54c 31.79 ± 2.89c 41.04 ± 9.40c Inactived
25 Inactived 2.57 ± 0.99b Inactived Inactived
26 Inactived 1.26 ± 0.42b Inactived 36.35 ± 1.36c
27 39.71 ± 1.48c 1.48 ± 0.61b 27.21 ± 1.77c Inactived
28 inactived 0.56 ± 0.01a,e Inactived Inactived
29 4.79 ± 0.28b 3.37 ± 0.96b 8.43 ± 2.79b 11.74 ± 4.97c
30 31.09 ± 8.91c 12.49 ± 2.47c 31.84 ± 8.13c 34.12 ± 0.97c
31 76.15 ± 1.77c 41.36 ± 2.89c 31.91 ± 9.76c 5.82 ± 0.85b
32 39.98 ± 4.03c Inactived Inactived 5.50 ± 0.61b,e
Etoposidef –g 30.16 ± 0.50 –g 0.051 ± 0.002
Doxorubixinf 0.83 ± 0.07 0.79 ± 0.08 0.44 ± 0.01 –g
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highest performance was achieved from the HuCCA-1 model showing Rcv  =  0.8957 
and RMSEcv =  0.2562 whereas the lowest performance was observed for A549 model 
(Rcv =  0.5958, RMSEcv =  0.4211). The experimental and predicted cytotoxic activities 
against four cancer cell lines (pIC50) are shown in Table 4 and Fig. 8.  
Prediction of cytotoxic activities of virtually modified compounds
In order to investigate the effects of structural modification on the core structures of 
triazoles as opened chain (1–15) and closed chain (16–32), a series of structural modi-
fied compounds (1A–1R, 2A–2R, 7A–7R and 8A–8R) were virtually constructed based 
on the changing substituents as shown in Fig. 7.
The modified compounds were drawn, geometrically optimized and calculated to 
obtain distinct sets of important descriptor values of each QSAR models (Additional 
file 2) for subsequently calculation of their predicted activities. The structurally modi-
fied compounds were categorized by their predicted cytotoxic activities as highly active 
(pIC50  >  0), moderately active (−1  <  pIC50  <  0) and weakly to inactive (pIC50  <  −1) 
(Prachayasittikul et al. 2014). The predicted cytotoxic activity (pIC50) of modified com-
pound series are shown in Additional file 3.
Understanding structure–activity relationships
Comprehensive consideration of experimental activities of the tested compounds (1–32) 
and predicted cytotoxic activities of modified compounds (1A–1R, 2A–2R, 7A–7R 
and 8A–8R, Figs. 3, 4, 5, 6) against four cancer cell lines along with their descriptor val-
ues were performed to understand the SAR. The effects of structural modifications by 
Table 2 Definition of descriptors using for development of QSAR models
Descriptor Type Definition
R5e+ GETAWAY descriptors R maximal autocorrelation of lag 5/weighted by Sanderson elec-
tronegativity
nArCOOR Functional group counts Number of esters (aromatic)
RDF105m RDF descriptors Radial Distribution Function—105/weighted by mass
MATS7m 2D autocorrelations Moran autocorrelation of lag 7 weighted by mass
MATS8v 2D autocorrelations Moran autocorrelation of lag 8 weighted by van der Waals volume
Lop lopping centric index Topological indices
R7m GETAWAY descriptors R autocorrelation of lag 7/weighted by atomic masses
Table 3 Summary of QSAR models and their predictive performances against four cancer 
cell line
pIC50 is the concentration of compound required for 50 % inhibition of cell growth
N number of data set, RTr correlation coefficient of the training set, RMSETr root mean square error of the training set,  
RCV correlation coefficient of leave‑one‑out cross validation (LOO‑CV) of the testing set, RMSECV root mean square error 
LOO‑CV of the testing set
Cell line Equation N RTr RMSETr RCV RMSECV
HuCCA-1 pIC50 = −84.0157(R5e+) + 1.0288(nArCOOR) + 0.8738 13 0.9597 0.1603 0.8957 0.2562
HepG2 pIC50 = 0.0784(RDF105 m) + 5.1878 (MATS7 m) − 1.7524 24 0.7537 0.4006 0.6724 0.4526
A549 pIC50 = 1.5979(MATS8v) + 0.9251(nARCOOR) − 1.7829 16 0.8673 0.2390 0.5958 0.4211
MOLT-3 pIC50 = 1.0649(Lop) + 10.3977(R7 m) − 5.6832 20 0.8936 0.1714 0.8430 0.2070
Page 9 of 22Prachayasittikul et al. SpringerPlus  (2015) 4:571 
changing substituents R and R1 (Figs. 2, 7) were observed and summarized in Additional 
file 4. The effects of substitutions on meta- and para-trizoles were compared based on 
the modified compound series obtaining the best improved activity against particular 
cancer cell line (Additional file 5).
HuCCA‑1 cell line
(1)pIC50 = −84.0157(R5e+)+ 1.0288 (nArCOOR)+ 0.8738
Table 4 Experimental and  predicted cytotoxic activities (pIC50) of  compounds 1–32 
against cancer cell lines
Exp. experimental activity, Pred. predicted activity
a Compounds determined to be experimentally inactive and were excluded from QSAR analysis
Compound HuCCA-1 HepG2 A549 MOLT-3
Exp. Pred. Exp. Pred. Exp. Pred. Exp. Pred.
1 −0.937 −1.004 −0.958 −1.571 −1.538 −1.345 –a –a
2 –a –a −1.760 −1.640 –a –a –a –a
3 –a –a −1.450 −1.543 –a –a −1.871 −1.797
4 –a –a −1.912 −1.514 –a –a –a –a
5 −1.944 −1.790 −2.002 −1.835 –a –a −1.505 −1.588
6 –a –a –a –a –a –a −1.788 −1.548
7 –a –a −1.619 −1.624 –a –a −1.535 −1.513
8 –a –a −1.694 −1.711 –a –a −0.945 −0.833
9 –a –a −1.760 −1.426 −1.899 −1.760 −0.965 −1.306
10 –a –a −1.538 −1.524 −1.592 −1.790 −1.014 −1.074
11 −1.207 −1.420 −1.095 −1.739 −1.292 −1.544 −1.949 −1.785
12 –a –a –a –a –a –a −1.027 −1.497
13 –a –a −1.378 −0.589 −1.260 −1.231 −1.785 −1.775
14 –a –a –a –a −1.448 −1.540 −1.241 −1.319
15 –a –a –a –a –a –a −1.004 −1.238
16 −1.711 −1.454 –a –a –a –a –a –a
17 –a –a −0.813 −1.241 –a –a –a –a
18 –a –a −1.782 −1.112 –a –a –a –a
19 –a –a –a –a −1.822 −1.498 –a –a
20 −1.479 −1.665 −1.281 −1.090 −1.173 −1.415 −1.340 −1.216
21 0.201 −0.306 −1.092 −0.858 0.244 −0.857 −1.270 −1.423
22 –a –a −0.722 −1.259 −1.771 −1.635 –a –a
23 −1.394 −1.051 –a –a −1.403 −1.252 −1.907 −1.640
24 −1.857 −2.031 −1.502 −1.431 −1.613 −1.524 –a –a
25 –a –a −0.410 −0.589 –a –a –a –a
26 –a –a −0.100 −0.859 –a –a −1.561 −1.604
27 −1.599 −1.652 −0.170 −0.456 −1.435 −1.449 –a –a
28 –a –a 0.252 −0.449 –a –a –a –a
29 −0.680 −0.173 −0.528 −0.590 −0.926 0.176 −1.070 −0.609
30 −1.493 −1.570 −1.097 −0.866 −1.503 −1.573 −1.533 −1.412
31 −1.882 −1.802 −1.617 −0.653 −1.504 −1.664 −0.765 −0.843
32 −1.602 −1.652 –a –a –a –a −0.740 −0.749
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The experimental results (Table 1) showed that the majority of the tested compounds 
(1–32) were weakly active or inactive against HuCCA-1 cell line except for ester com-
pounds 21 (highly active), 1 (moderately active) and 29 (moderately active). Particularly, 
ester compound 21 was the most potent compound affording less IC50 value (0.63 µM) 
than the reference drug, doxorubicin (0.83  µM), followed by compound 29 as second 
ranked. The effect of opened/closed chain core structures were found in compounds 
8 and 21 which are the compounds containing the same substituents (R) while bear-
ing different core structures, opened chain (8) or closed chain (21), Fig.  2. Interest-
ingly, the closed chain structure can shift the activity of the compound from inactive 
(8, opened chain) to highly active (21, closed chain). Moreover, compound 21 exhibited 
more potent activity than compound 29 (IC50 4.79 µM) indicating that the replacement 
of H atoms (R1) in aromatic ring by methoxy (OCH3) groups can deteriorate the activ-
ity. The similar effects can be observed in compound 24 as compared to compound 16. 
However, in some cases, the methoxy substituents (R1) can improve activity by changing 
inactive compounds to active compounds such as compound 19 (inactive) to 27 (active), 
and 22 (inactive) to 30 (active). Certain functional groups (R) were observed to influ-
ence the activity of particular compounds. It was found that replacement of naphthale-
nyl group in compound 3 (inactive) by 7-coumaryl group gives rise to improved activity 
of compound 11 (IC50 16.12 µM) whereas 4-coumaryl substituent leads to inactive com-
pound 12. In addition, the effect of the closed chain was noted to improve activity of 
Fig. 8 Plots of experimental versus predicted pIC50 values of cytotoxic activities against four cell lines (a 
HuCCA-1, b HepG2, c A549, d MOLT-3) generated by QSAR models (training set: compounds are represented 
by closed circle and regression line is shown as a solid line, leave-one-out validated testing set: compounds are 
represented by opened hex and regression line is shown as a dotted line)
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4-coumarin analogs as found in compound 23 (IC50 24.80  µM) when compared to 
opened chain compound 12 (inactive).
The QSAR analysis revealed that descriptors pertaining to the electronegativity 
(R5e+) and the number of aromatic esters (nArCOOR) of the compounds influenced 
the cytotoxic activity against HuCCA-1 cell line, Eq.  1. The R5e+  descriptor was the 
most influential descriptor as represented by its high regression coefficient. The nega-
tive regression coefficient of R5e+ (−84.0157) and positive regression coefficient of nAr-
COOR (1.0288) indicate that low electronegativity and high number of aromatic esters 
are required for preferable cytotoxic activity. It was observed that compounds with high 
value of R5e+ exhibited poor activity. For example, ketone 7D (ArCOCF3, Fig. 5) with 
high electronegativity atom (F), which had the highest value of R5e+ (0.057, Additional 
file 2) amongst all modified compounds, exhibited the worst activity with pIC50 value of 
−3.915 (Additional file 3). The presence of aromatic esters was found to be important for 
potent activity as seen in compounds 21, 29 and modified compounds (ArCOOCF3) in 
series 8 (8A–8R) as shown in Fig. 6.
Considering the predicted cytotoxic activity of modified compounds (Additional file 3) 
and experimental activity of their prototypes (Table  4), the structural modification of 
compound 1 reduce cytotoxic activity. The experimental inactive compounds (2 and 
7) afforded modified compounds (2A–2R and 7A–7R) that possessed weakly to inac-
tive cytotoxic activity. Although the tested compound 8 contains aromatic ester, which 
is represented by nArCOOR descriptor value, it was found to be experimentally inac-
tive. However, the improved activities of modified compounds in series 8 (8A–8R) were 
predicted when compared to their inactive prototype (8). Notably, the ester 8N (pIC50 
0.054) was noted as the most potent compound among all modified compound series. 
It was observed that particular forms (opened/closed chain), substituents R (phenox-
yester), R1 (H, OH, OCH3) and R2 (1-adamantyl, phenyl) on the meta- and para- tria-
zoles influence the R5e+ value of the compounds in governing their cytotoxic activities. 
For both para- and meta- modified compounds in series 8, closed chain analogs (8E, 
8G, 8N and 8P) were predicted to exhibit more potent cytotoxic activity (indicated by 
pIC50 value) than opened chain analogs (8A, 8C, 8J and, 8K) and the 1-adamantyl (R2) 
derivatives (8H and 8R) were predicted to be more active than phenyl (R2) derivatives 
(8D and 8M). In case of the opened chain analogs (8A, 8B, 8C, 8J, 8K and 8L), most 
of the compounds with para-triazole were predicted as more potent compounds than 
the compounds with meta-triazole as indicated by pIC50 values i.e., 8A (−0.618)  > 8J 
(−1.038) and 8B (−0.786) > 8K (−1.122) except for the case of phenyl (R2) compounds 
in which the large improved activity of meta-triazole 8M (−0.618) was observed as com-
pared to the para-triazole 8D (−2.466). In contrast, the closed chain meta-triazole com-
pounds (8N and 8P) and 1-adamantyl meta-triazole compound (8R, pIC50 −0.282) were 
found to exhibit more potent activity than the corresponding closed chain para-triazoles 
(8E and 8F, pIC50 −0.114 and −0.786, respectively) and 1-adamantyl (R2) para-triazole 
compound (8H, pIC50 −0.702).
The most potent ester (COOCF3) 8N is the closed chain meta-triazole (R1=H), which 
had the lowest R5e+ value (0.022) among the modified compounds. The most potent 
para-triazole methyl ester (COOCH3) 21 (R1=H) had lower value of R5e+ (0.023) than 
its methoxy analog 29 (R1 = OCH3, R5e+ = 0.028), thereby giving rise to higher potency 
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of 21. In contrast, the opened chain para-triazole ester (COOCH3) 8 (R1=H) exhibited 
no cytotoxic activity. This could be possibly explained that the cytotoxic activity against 
HuCCA-1 cell required the molecule with low electronegativity (R5e+) and less flexibil-
ity or more rigidity in interacting with the target site of action as observed in compound 
21 comparing to its opened chain analog 8 (inactive compound).
HepG2 cell line:
Results showed that most of the tested compounds (1–32) exhibited more potent cyto-
toxic activity against HepG2 cell lines than the reference drug, etoposide (Table 1). The 
closed chain analogs (17, 20–22 and 25–30) displayed higher activity as compared to 
the opened chain analogs (1, 3, 11 and 13). Particularly, compound 28 was noted as the 
best compound affording less IC50 value (0.56  µM) than both reference drugs, etopo-
side (30.16 µM) and doxorubicin (0.79 µM). It was found that introducing the NO2 and 
4-coumaryl moieties into the phenoxy ring of compound 2 leads to inactive cytotoxic 
activity of compounds 6 and 12, respectively. It was observed that the substitution of 
OCH3 (R1) on aromatic ring increases cytotoxic activity of the compounds except for 
compounds 13, 14, and 30. In contrast to HuCCA-1 cell line, the substitution of OCH3 
on the aromatic ring (R1) can markedly increase the value of MATS7 giving rise to an 
improved activity of compound 29 (MATS7 = 0.040, Additional file 2 and IC50 = 3.37, 
Table 1) when compared to non-substituted (R1=H) compound 21 (MATS7 = −0.020, 
Additional file 2 and IC50 = 12.36, Table 1) as represented by approximately fourfolds 
reduced IC50 value. Among the experimental tested compounds, the closed chain deriv-
atives exhibited more potent activity than that of the opened chains, except for closed 
chain compound 19 (inactive) comparing to its opened chain analog 7 (active). In addi-
tion, it should be noted that the para-position of CH3 on the phenoxy ring (28) has 
greater influence on enhancing the cytotoxic activity of the compound than the ortho-
position (27).
The QSAR analysis revealed that mass descriptors i.e., RDF105m and MATS7m, are 
important descriptors for cytotoxic activity against HepG2 cell line, Eq.  2. The higher 
regression coefficient of MATS7m (5.1878) indicated its greater influential effect. 
The QSAR equation indicated that high values of RDF105m and MATS7m are essen-
tial for potent cytotoxic activity. For example, the highest RDF value (14.609) together 
with high MATS7m value (0.064) were found in the most potent compound (28) in the 
tested series, Additional file 2. Similarly, the most potent predicted cytotoxic activity of 
the modified compounds was noted in compound 1P which had the high RDF values of 
18.976.
Improved cytotoxic activities were predicted from all series of the modified com-
pounds in which the most enhanced effects were noted for the modified compounds 
in series 1 and 7. Compound 1P was predicted as the most potent compound of the 
modified series followed by compound 7F affording pIC50 values of −0.151 and −0.163, 
respectively (Additional file 3). Considering the modified series 1 and 7 (Figs. 3, 5, 7), 
the 1-adamantyl (R2) substituted (H and R) and closed chain (E, F, G, N, P and Q) 
(2)pIC50 = 0.0784 (RDF105m)+ 5.1878 (MATS7m)+ 1.7524
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compounds are more potent cytotoxic agents against HepG2 cell line than the phenyl 
(R2) substituted (D and M) and opened chain (A, B, C, J, K and L) compounds except for 
the compounds in series 7 (7N and 7P). The better predicted activities were observed 
in the opened chain analogs i.e., 7J and 7K comparing to the closed chain analogs 7N 
and 7P (Additional file 3). For the opened chain in series 1 (A, B, C, J, K and L), phenyl 
(R2) substituted compounds (D and M) and 1-adamantyl (R2) substituted compounds 
(H and R), it was found that the meta-triazoles (J, K, L, M and R) exhibited better activi-
ties than the para-triazoles (A, B, C, D and H). For closed chain compounds (E, F, G, 
N, P and Q), the meta-triazole of series 1 (1N, 1P and 1Q) exerted more potent activ-
ity than para-triazole (1E, 1F and 1G). In contrast, the para-triazole of series 7 (7E, 7F 
and 7G) exhibited better activity than the meta-triazole (7N, 7P and 7Q). Particularly, 
compound 7F afforded the predicted pIC50 value approximately tenfolds greater than 
7P (7F: pIC50 = −0.163, 7P: pIC50 = −1.177, Additional file 3). In addition, the effects 
of para-triazole with closed chain and 1-adamantyl substituent (R2) on improving cyto-
toxic activity were generally observed via increased MATS7m values when compared to 
opened chain and phenyl (R2) substituted triazoles whereas that of meta-triazoles were 
governed by increased RDF105m values when compared to para-triazoles (Additional 
file 2).
Cytotoxic activity of meta- and para-triazoles are governed by substituents R, R1 and 
R2 in providing high values of descriptors (MATS7m and RDF105m) weighted by mass. 
Obviously, the most potent compounds 28 and 1P constitute the same methoxy group 
(R1=OCH3), and R=para-methylphenoxymethyl and para-trifluoromethylphenoxy for 
28 and 1P, respectively. Such substituents (R and R1) enhanced masses on to the triazole 
core structures.
A549 cell line
Similar to the HuCCA-1 cell line, the majority of the tested compounds (1–32) exhibited 
weakly active and inactive cytotoxic activities against A549 cell line (Table 1). However, 
the ester compound 21 (highly active) was noted as the most potent cytotoxic agent 
followed by ester compound 29 (moderately active). It was found that closing the ring 
caused dramatically changes in activity shifting from inactive to active compounds. The 
notable effect was observed when compared the opened chain ester 8 (inactive) and 
closed chain ester 21 (highly active). Furthermore, the relative position of OCH3 and 
CHO on the substituted phenoxy ring was noted for its influence on cytotoxic activity 
in which these functional groups were suggested to be placed in para-position to each 
other as observed for compound 31 (active) rather than in meta-position as seen in 
compound 32 (inactive).
The QSAR analysis revealed that van der Waals volume descriptor (MATS8v) and the 
number of aromatic esters (nArCOOR) are important descriptors for cytotoxic activ-
ity against A549 cell line, Eq. 3. The positive regression coefficients of both descriptors 
indicated that high values are essential for potent cytotoxic activity of the compounds. 
The effects of substituents (R, R1) in the tested compound series (1–32) were observed 
(3)pIC50 = 1.5979 (MATS8v)+ 0.9251 (nArCOOR)− 1.7829
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via an alteration of MATS8v values. For example, the insertion of carbonyl group to the 
CH3 group of compound 19 (MATS8v =  0.164, Additional file  2 and IC50 66.30  µM, 
Table 1) provided the ketone compound 20 (IC50 14.90 µM) with approximately twofold 
increased MATS8v value (0.249, Additional file  2) giving rise to its improved activity 
when compared to compound 19. Interestingly, replacement of CH3 group of compound 
19 by COOCH3 gave the most potent compound 21 with the highest MATS8v (0.348) 
amongst the tested compounds (1–32). The potency of these compounds (19–21) are 
shown to be 21 > 20 > 19 with the MATS8v values of 0.348, 0.249 and 0.164, respec-
tively. Similar findings of more active compounds possessing the higher MATS8v values 
were found, for example, compounds 10 > 9 and 27 > 28 (Additional file 4).
The structurally modified compounds in series 1 and 8 were predicted to be more 
potent compounds than their prototypes. Notably, all of the modified compounds in 
series 8 were predicted as moderately active compounds (Additional file 3) which may 
be governed by the presence of the aromatic ester in the molecule, as represented by 
the nArCOOR values (Additional file 2). Ester compounds 8G and 8B were noted as the 
most (MATS8v =  0.150) and the second most (MATS8v =  0.146) potent compounds 
among all modified compounds, respectively (Additional file  3). Apparently, both 
opened and closed chain para-triazole analogs of the modified compounds in series 8 
exhibited more potent activities than their meta-triazole analogs (Additional file 5). The 
closed chain compounds (E, G and N, Fig. 6) were predicted to be more active than the 
opened chain compounds (A, C and J, Fig. 6) except for the opened chain analogs 8B 
and 8K were predicted as more potent compounds than the closed chain derivatives 
8F and 8P, Additional file  4. However, effect of opened/closed chain were not clearly 
observed for OH (R1) substituted compounds 8L (opened chain, pIC50 = −0.779, Addi-
tional file 3) and 8Q (closed chain, pIC50 = −0.778, Additional file 3) as represented by 
their comparable pIC50 values. For both para- and meta- analogs of all modified series 
(Fig.  6), 1-adamantyl (R2) substituted compounds exhibited more potent activity than 
phenyl (R2) substituted compounds, except for series 1. The phenyl (R2) substituted 
compound of meta-series, compound 1M, was more potent than its 1-adamantyl (R2) 
analog 1R (Additional file 4). No effect of changing substituted ring type (R2) was found 
for para-series as observed from comparable cytotoxic activities of compounds 1H and 
1D, Additional file 4.
The most potent esters 21 (COOCH3, R1=H) and 8G (COOCF3, R1=OH) are para-
triazoles, in which both compounds had the highest values of MATS8v in their tested 
and modified series compounds, respectively.
MOLT‑3 cell line
 
Among the tested compounds (1–32), only compounds 8, 9, 31 and 32 were noted as 
moderately active cytotoxic agents against MOLT-3 cell line while the rest were listed 
as inactive to weakly active compounds. The findings suggested that the substitution of 
CO2CH3, OCH3 and CHO moieties on the phenoxylmethyl group (R) may essential for 
cytotoxic activity of the compounds. Interestingly, the effects of certain moieties and 
(4)pIC50 = 1.0649(Lop)+ 10.3977(R7m)− 5.6832
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isomeric forms on cytotoxic activity against the MOLT-3 cell line were found in contrast 
to other tested cell lines i.e., HuCCA-1, HepG2 and A549. Particularly, m-substitution 
of OCH3 and CHO on phenoxy (R) group exerted the most potent activity as noted for 
closed chain compound 32 comparing to p-substitution of compound 31 (Additional 
file 4). Similar isomeric effect of OCH3 and CHO was found in opened chain analogs of 
meta- (9) and para- (10) in which 9 exhibited more potent activity than 10. In addition, 
the replacement of naphthalenyl moiety in the opened chain triazoles (3) by 7-coumaryl 
moiety gave compound 11 with loss of the cytotoxic activity (3 > 11). However, more 
potent activity can be obtained by substitution of 4-coumaryl rather than 7-coumaryl 
(12  >  11), Table  1. Furthermore, opened chain triazole of 4-coumaryl (12) exhibited 
better activity when compared to the same substitution (R) on the closed chain triazole 
(23).
The QSAR analysis indicated that topological index (Lop) and atomic masses descrip-
tor (R7m) were influential descriptors for affecting the cytotoxic activity against MOLT-3 
cell line, Eq. 4. Regarding the regression coefficient of R7m, the importance of the atomic 
masses of the compounds were noted. The effect of functional group substitution affect-
ing the R7 m values were obviously seen in closed chain (R1=OMe) compounds 31 and 
32 in which both compounds possess the same value of Lop (0.876, Additional file 2) 
but different values of R7m (31 = 0.377, 32 = 0.385, Additional file 2). It was observed 
that the relative positions of OCH3 and CHO on the phenoxylmethyl ring (R) affects the 
R7 m values. The higher value of R7m was observed when these two functional groups 
are placed in meta-position to each other thereby giving rise to more potent activity 
(32 > 31, Fig. 2, Additional file 3). Similar substitution effects of OCH3 and CHO on the 
R group afforded the same Lop value (0.740) were noted for opened chain (R1=H) com-
pounds 9 and 10. However, meta-substitution of OCH3 and CHO (9) displayed higher 
activity with relative lower R7m value as compared to para-substitution on the R group 
of 10.
It was found that the structural modifications can improve the activities of all modi-
fied compounds (Table 4 and Additional file 3) when compared to their prototypes (1, 
2, 7 and 8) except for 1-adamantyl analog (R2) of compound 7, 7H affording pIC50 value 
of −1.865 (Additional file 3) while that of 7 was −1.513 (Table 4). The best enhancing 
effects were found in modified compounds series 8 in which most of the compounds 
were predicted as highly active (Additional file 3). Interestingly, closed chain (R1=OH, 
R=ortho-ester) of m-triazole compound 8Q (R7m  =  0.537) and of p-triazole 8G 
(R7m = 0.519) had the same value of Lop (0.983), and were found to be the most and the 
second most potent compounds of all modified series, respectively. However, none of 
them exhibited more potent activity than the reference drug, etoposide. Considering the 
modified compounds series 8, the closed chain triazole derivatives (8F, 8G, 8P and 8Q) 
exhibited more potent cytotoxic activity than the opened chain analogs except for 8A 
and 8J (8A > 8E and 8J > 8N). The notably enhanced effect was observed in the closed 
chain hydroxyl (R1) derivative 8Q as represented by its 8.61-folds pIC50 value (0.947) 
greater than the opened chain compound 8L (0.110), Additional file 3.
A variety of structural modification effects on cytotoxic activity against the MOLT-3 
cell line can be observed through para- and meta-triazoles (Additional file  5). It was 
noted that both meta- and para-triazoles influence the cytotoxic activity via the 
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alteration of R7m values in which the more active compounds possess the higher val-
ues of R7m but equal Lop as compared to the less active ones (Additional files 2, 3). For 
example, meta-triazole compound 8M (R2=phenyl) with higher R7m value was approxi-
mately twofold more potent than para-triazole of phenyl (R2) compound 8D (R7m; 
8M = 0.397, 8D = 0.365, Additional file 2 and pIC50; 8M = −0.485, 8D = −0.818, Addi-
tional file 3). The 1-adamantyl (R2) substitution in para-triazole core structure enhances 
cytotoxic activity as represented by 2.456 folds increased pIC50 value of compound 8H 
(pIC50 = −0.333, Additional file  3) as compared to the phenyl (R2) substituted para-
compound 8D (pIC50 = −0.818, Additional file 3). In contrast, the phenyl (R2) substi-
tuted meta-triazole compound 8M exhibited better activity than the 1-adamantyl (R2) 
substituted meta-triazole compound 8R (pIC50: 8M = −0.485, 8R = −0.645, Additional 
file 3).
The most potent compounds (32 and 8Q) against MOLT-3 cell are para-triazole 
(R1=OCH3, R=phenoxyaldehyde) and meta-triazole (R1=OH, R=phenoxyester), 
respectively. It is notable that a carbonyl (CO) group of the aldehyde 32 may act as 
electrophilic center in interacting with nucleophile at the target site of action. Similar 
interaction could possibly be seen in the CO group of ester 8Q with nucleophilic site 
of action. These findings suggested that particular isomers in combination with certain 
functional groups (R2) are required for preferable cytotoxic activity of the compounds. 
The promising compounds to be further developed as anticancer agents against each 
cancer cell line are summarized in Table 5, obviously, meta- triazoles 8N, 1P and 8Q for 
HuCCA-1, HepG2 and MOLT-3 cell lines, respectively, and para- triazole 8G for A549 
cell line.
Conclusion
Understanding structure–activity relationships of the compounds is essential for effica-
cious design and development of drugs. Herein, the QSAR was used as a tool for inves-
tigating the effects of structural modifications on the cytotoxic activity of the triazole 
derivatives. Four QSAR models were successfully constructed using the chemical struc-
tures and the experimental cytotoxic activities of a set of triazole derivatives (1–32). 
The acceptable predictive performances were obtained affording RCV values ranging 
from 0.5958 to 0.8957 and RMSECV ranging from 0.2070 to 0.4526. The QSAR models 
revealed a set of important descriptors that represented distinct properties influencing 
the cytotoxic activity against particular cell lines i.e., electronegativity, number of aro-
matic ester, van der Waals volume, topological indice and atomic masses. The effects 
of meta-/para-triazoles, the opened/closed chain core structure and particular substitu-
ents (R, R1, R2) affecting the cytotoxic activities of the compounds were investigated by 
virtual construction of an additional set of structurally modified compounds (1A–1R, 
2A–2R, 7A–7R and 8A–8R) in which their cytotoxic activities were predicted using the 
constructed QSAR models obtained from the tested compounds. The findings indicated 
a set of potential compounds for further development as summarized in Table 5. The 
study provided insights into the SAR of the triazole derivatives and their cytotoxic activ-
ities. The influential moieties and isomers for preferable activity, and a set of promising 
compounds for further development were indicated for the benefit of guiding the design, 
synthesis and development of novel triazole-based anticancer agents.
Page 17 of 22Prachayasittikul et al. SpringerPlus  (2015) 4:571 
Methods
Conceptually, a series of predictive QSAR models were constructed using data sets 
obtained from experimentally tested compounds (1–32, Figs. 1, 2) (Pingaew et al. 2014a, 
b) and were subsequently used for prediction of additional structurally modified com-
pounds (1A–1R, 2A–2R, 7A–7R and 8A–8R, Fig. 3, 4, 5, 6) generated in silico. The con-
ceptual framework is shown in Fig.  9. Initially, the molecular structures of the tested 
compounds (1–32) were drawn, geometrically optimized and calculated to obtain a large 
set of descriptor values. Hence, feature selection was performed to select only informa-
tive ones which were further used as predictors (X) to predict anticancer activity (Y). 
These X (descriptors) and Y (cytotoxic activity) blocks of data were subsequently used 
for development of QSAR models. Likewise, the construction, geometrical optimization 
Table 5 A summary of potential compounds for further development
Cell line Tested / 
modified






















































































c Potent than reference drug
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and calculation were performed in the same manner with the structurally modified com-
pounds (1A–1R, 2A–2R, 7A–7R and 8A–8R) to obtain their descriptor values. Finally, 
the QSAR equations constructed by the tested compounds (1–32) were used to calcu-
late predicted activities of modified compounds (1A–1R, 2A–2R, 7A–7R and 8A–8R).
Data sets
A set of triazole derivatives (1–32) and their experimental IC50 values against four can-
cer cell lines i.e., HuCCA-1, HepG2, A549 and MOLT-3 (Table 1) were obtained from 
literature reported by our research group (Pingaew et al. 2014a, b). In order to obtain 
normal distribution of data points, the IC50 values were converted to pIC50 values by tak-
ing the negative logarithm to the base of 10 (−log IC50). With respect to the anticancer 
activity against four cancer cell lines, four data sets were arranged for the construction of 
separated QSAR models. For each data set, the compounds exhibited inactive cytotoxic 
activity were excluded from the analysis.
Molecular structure optimization and descriptor calculation
The rationale for geometrical optimization is to obtain low-energy conformers for inves-
tigated compounds that will subsequently be used for calculation of molecular descrip-
tors. Chemical structures of the 32 tested compounds (1–32) and 64 virtually modified 
compounds (1A–1R, 2A–2R, 7A–7R and 8A–8R) were drawn by the GaussView soft-
ware (Dennington et al. 2003) and initially geometrically optimized using Gaussian 09 
(Frisch et al. 2009) at the semi-empirical Austin Model 1 (AM1) level followed by density 
functional theory (DFT) calculation using the Becke’s three-parameter hybrid method 
with the Lee–Yang–Parr correlation functional (B3LYP) together with the 6–31  g(d) 
level. A set of quantum chemical descriptors consisted of the mean absolute atomic 
charge (Qm), total energy (Etotal), total dipole moment (μ), highest occupied molecular 
orbital energy (EHOMO), lowest unoccupied molecular orbital energy (ELUMO), energy 
difference of HOMO and LUMO (HOMO-LUMOGap), electron affinity (EA), ioniza-
tion potential (IP), Mulliken electronegativity (χ), hardness (η), softness (S), electro-
philic index (ωi) and electrophilicity (ω) were extracted using an in-house developed 
script. A set of 3224 molecular descriptors were calculated from optimized molecular 
structures using Dragon software (version 5.5) (Talete 2007). The molecular descriptors 
obtained from Dragon are comprised of 22 classes as follows: Constitutional descriptors, 
Fig. 9 Workflow of the study
Page 19 of 22Prachayasittikul et al. SpringerPlus  (2015) 4:571 
Topological descriptors, Walk and path counts, Connectivity indices, Information indi-
ces, 2D autocorrelation, Edge adjacency indices, Burden eigenvalues, Topological charge 
indices, Eigenvalue-based indices, Randic molecular profiles, Geometrical descriptors, 
RDF descriptors, 3D-MoRSE descriptors, WHIM descriptors, GETAWAY descriptors, 
Functional group counts, Atom-centred fragments, Charge descriptors, Molecular prop-
erties, 2D binary fingerprints and 2D frequency fingerprints.
Feature selection
The correlation-based feature selection was performed to select informative descriptors 
from a large set of calculated descriptors. Initially, the pair-correlation of each descriptor 
value and bioactivity (pIC50) was calculated from an initial set of descriptors consist-
ing of 13 quantum chemical descriptors and 3224 molecular descriptors. The correlation 
coefficient (r) value of 0.6 was used as a cut-off value for initial selection. Descriptors 
with |r|  <  0.6 were considered as low correlated descriptors and were excluded from 
the study whereas those with |r| ≥ 0.6 were selected for further selection process. The 
remaining descriptors along with their bioactivity (pIC50) were used as an input data for 
feature selection by stepwise multiple linear regression (MLR) as implemented in SPSS 
statistics 18.0 (SPSS statistics 18.0 2009). Finally, a set of important descriptors were 
obtained for multivariate analysis using MLR.
Multivariate analysis using MLR
Multivariate analysis was performed by MLR using selected descriptors as independent 
variables (X) and pIC50 values as dependent variable (Y). The MLR models were con-
structed by Waikato Environment for Knowledge Analysis (WEKA) version 3.4.5 (Wit-
ten et al. 2011) according to the following equation:
where Y is the pIC50 values of compounds, B0 is the intercept and Bn are the regression 
coefficient of descriptors Xn.
Data sampling
The data set was divided into 2 subsets i.e., training set and testing set by means of leave-
one-out cross validation (LOO-CV). Conceptually, one sample was removed from the 
whole data set (N) and were used as the testing set while the remaining samples (N-1) 
were used as the training set. The same process was continued until every sample in the 
data set was iteratively used as the testing set to predict Y variable.
Evaluating the performance of QSAR models
The predictive performances of the QSAR models were assessed by two statistical 
parameters i.e., correlation coefficient (R) and root mean square error (RMSE). The first 
parameter (R) represented the predictive performance whereas the later (RMSE) repre-
sented predictive error of the models.
(5)Y = B0 +
∑
BnXn
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Prediction of structurally modified compounds by the constructed QSAR models
Regarding the obtained QSAR equations, the descriptor values of 64 structurally modi-
fied compounds (1A–1R, 2A–2R, 7A–7R and 8A–8R) obtained from Gaussian and 
Dragon calculations were used as independent variable (X) for computing their pre-
dicted anticancer activity (pIC50 values) against the four tested cancer cell lines.
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